In:
Arteriosclerosis, Thrombosis, and Vascular Biology, Ovid Technologies (Wolters Kluwer Health), Vol. 28, No. 12 ( 2008-12), p. 2195-2201
Abstract:
To examine the role of CCR2 in the development of obesity and type 2 diabetes, we studied the effect of inhibition of CCR2 by propagermanium treatment in db/db mice. Propagermanium improved obesity-related metabolic disorders, implicating that inhibition of CCR2 improves obesity and type 2 diabetes by interfering adipose tissue inflammation.
Type of Medium:
Online Resource
ISSN:
1079-5642
,
1524-4636
DOI:
10.1161/ATVBAHA.108.168633
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2008
detail.hit.zdb_id:
1494427-3